Health & Biotech
PharmAust pushes forward with lead drug monepantel, four clinical trials to rollout
Health & Biotech
With a big year ahead, excitement is building for Dimerix’s global COVID-19 studies where results are due this quarter
Health & Biotech
Opin season arrives for patients as AI drives Opyl boom in Q2 receipts
Health & Biotech
ECS Botanics doesn’t miss a beat with more strong revenue growth as momentum continues to build
Health & Biotech
Osteopore delivers strong sequential quarterly sales growth, expects further traction as pandemic restrictions loosen
Experts
SocPo’s Powerplays: A few healthcare gems among the carnage
Health & Biotech
Diagnostic stock Atomo soars 12pc after scoring RAT distribution rights in New Zealand
Health & Biotech
RedLeaf: Singular has a sweet slice of the global VR, AI medical imaging pie
Health & Biotech
ASX Health Stocks: Weed stock Cann Group gets licence from TGA for its cannabis facility
Health & Biotech
EZZ to focus on combating cancer-causing digestive tract bacteria
Health & Biotech
Emerald hydrogen could supercharge Pure Hydrogen
Health & Biotech
ASX Health Stocks: Clinical trials gather pace for Visioneering Tech, Anteris and other biotechs
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.